

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

1-31 (cancelled).

32. (new) An isolated peptide less than about 50 amino acids in length, wherein said peptide comprises an epitope or analog derived from a tumor associated antigen, and wherein said antigen is selected from the group consisting of: carcinoembryonic antigen (CEA), p53, HER2/neu, MAGE 2 and MAGE 3.

33. (new) A composition comprising the peptide of claim 32 and a carrier.

34. (new) The composition of claim 33, further comprising a CTL-inducing peptide.

35. (new) The composition of claim 34, wherein said CTL-inducing peptide also comprises an epitope or analog derived from a tumor associated antigen selected from the group set out in claim 32.

36. (new) The composition of claim 33, further comprising a T helper peptide.

37. (new) The composition of claim 36, wherein said T helper peptide is a pan-DR binding epitope.

38. (new) A composition comprising at least three peptides, wherein each of said peptides comprises an epitope or analog derived from a tumor associated antigen selected from the group set out in claim 32.

39. (new) The composition of claim 33, further comprising a liposome, wherein said peptide is on or within said liposome.

40. (new) The composition of claim 33, further comprising a lipid.

41. (new) The composition of claim 33, wherein said peptide is linked to a spacer molecule.

42. (new) The composition of claim 33, further comprising an antigen presenting cell, wherein said peptide is on or within said antigen presenting cell.

43. (new) The composition of claim 42, wherein said antigen presenting cell is a dendritic cell.

44. (new) A polypeptide comprising at least a first epitope and a second epitope, wherein said first epitope comprises an epitope or analog derived from a tumor associated antigen selected from the group set out in claim 32.

45. (new) A composition comprising the polypeptide of claim 44, wherein each of said first epitope and said second epitope comprises an epitope or analog derived from a tumor associated antigen selected from the group set out in claim 32.

46. (new) A composition comprising the polypeptide of claim 44, wherein said polypeptide is a homopolymer.

47. (new) A composition comprising the polypeptide of claim 44, wherein said polypeptide is a heteropolymer.

48. (new) An isolated nucleic acid encoding the peptide of claim 32.

49. (new) An isolated nucleic acid encoding the polypeptide of claim 44.

50. (new) A method of treating or preventing cancer in a mammal comprising
administering the peptide of claim 32 to a mammal in need thereof.

51. (new) A method of treating or preventing cancer in a mammal comprising
administering the nucleic acid of claim 48 to a mammal in need thereof.